Regulus Therapeutics (NASDAQ:RGLS) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.06), MarketWatch Earnings reports. Regulus Therapeutics had a negative return on equity of 311.60% and a negative net margin of 75,823.62%.
Shares of RGLS opened at $1.12 on Tuesday. Regulus Therapeutics has a twelve month low of $0.80 and a twelve month high of $10.44. The firm has a market capitalization of $10.24 million, a PE ratio of -0.10 and a beta of 2.26.
A number of research firms recently weighed in on RGLS. Wedbush set a $2.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Friday, January 25th. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $1.38.
In other news, Director Stelios Papadopoulos acquired 50,000 shares of Regulus Therapeutics stock in a transaction dated Friday, December 28th. The shares were acquired at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the acquisition, the director now owns 835,073 shares of the company’s stock, valued at $910,229.57. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.40% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/03/19/regulus-therapeutics-rgls-posts-earnings-results-misses-estimates-by-0-06-eps.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
See Also: Guidelines for Successful Channel Trading
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.